AU2002221515A1 - A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it - Google Patents

A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it

Info

Publication number
AU2002221515A1
AU2002221515A1 AU2002221515A AU2151502A AU2002221515A1 AU 2002221515 A1 AU2002221515 A1 AU 2002221515A1 AU 2002221515 A AU2002221515 A AU 2002221515A AU 2151502 A AU2151502 A AU 2151502A AU 2002221515 A1 AU2002221515 A1 AU 2002221515A1
Authority
AU
Australia
Prior art keywords
angiostatin
virus
factor
high efficiency
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221515A
Inventor
Xiaoyan Che
Qijun Qian
Shuntong Shan
Mengchao Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIRGENE BIOTECHNOLOGY Ltd
Original Assignee
VIRGENE BIOTECHNOLOGY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIRGENE BIOTECHNOLOGY Ltd filed Critical VIRGENE BIOTECHNOLOGY Ltd
Publication of AU2002221515A1 publication Critical patent/AU2002221515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
AU2002221515A 2000-12-01 2001-11-30 A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it Abandoned AU2002221515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN00127680 2000-12-01
CNB001276808A CN1183250C (en) 2000-12-01 2000-12-01 Virus with specigic reproduction in tumor well and effective expression of tumor angiogenesis inhibitor and its construction method
PCT/CN2001/001596 WO2002044347A1 (en) 2000-12-01 2001-11-30 A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it

Publications (1)

Publication Number Publication Date
AU2002221515A1 true AU2002221515A1 (en) 2002-06-11

Family

ID=4592692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221515A Abandoned AU2002221515A1 (en) 2000-12-01 2001-11-30 A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it

Country Status (9)

Country Link
US (1) US20040091996A1 (en)
EP (1) EP1347042A1 (en)
JP (1) JP2004513663A (en)
KR (1) KR20030081338A (en)
CN (2) CN1183250C (en)
AU (1) AU2002221515A1 (en)
CA (1) CA2430625A1 (en)
WO (1) WO2002044347A1 (en)
ZA (1) ZA200304195B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163292B2 (en) * 2007-02-16 2012-04-24 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
CN101781636A (en) * 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 Proliferous type recombination oncolytic adenovirus containing 11-type adenovirus cilia protein gene, construction method and application thereof
SI3029144T1 (en) 2009-03-02 2019-11-29 Univ California Tumor-selective adenovirus e1a and e1b mutants
WO2018218083A1 (en) * 2017-05-24 2018-11-29 Epicentrx, Inc. Anti-angiogenic adenovirus
US20210023152A1 (en) * 2018-03-30 2021-01-28 Tomoki Todo Swelling-Suppressive Oncolytic Virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0437481B1 (en) * 1988-10-04 1995-03-15 PETROS Peter Emmanuel Surgical instrument prosthesis
US5972000A (en) * 1992-11-13 1999-10-26 Influence Medical Technologies, Ltd. Non-linear anchor inserter device and bone anchors
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5899909A (en) * 1994-08-30 1999-05-04 Medscand Medical Ab Surgical instrument for treating female urinary incontinence
JP2001523103A (en) * 1997-04-28 2001-11-20 ローヌ−プーラン・ロレ・エス・アー Intratumoral delivery of angiogenic antagonists for tumor therapy by adenovirus
US6475139B1 (en) * 1999-06-09 2002-11-05 Ethicon, Inc. Visually-directed surgical instrument and method for treating female urinary incontinence

Also Published As

Publication number Publication date
CN1183250C (en) 2005-01-05
US20040091996A1 (en) 2004-05-13
JP2004513663A (en) 2004-05-13
KR20030081338A (en) 2003-10-17
CA2430625A1 (en) 2002-06-06
CN1478143A (en) 2004-02-25
WO2002044347A1 (en) 2002-06-06
EP1347042A1 (en) 2003-09-24
ZA200304195B (en) 2004-04-08
CN1298947A (en) 2001-06-13

Similar Documents

Publication Publication Date Title
AU2002338666A1 (en) Multiplication of viruses in a cell culture
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
GB2378591B (en) RF power amplifier and methods for improving the efficiency thereof
GB2372627B (en) Fuel cell and fuel cell stack
AU2001213236A1 (en) Mini-cyclone biocollector and concentrator
AUPQ801700A0 (en) Enzyme and viral activation
EP1519431A4 (en) Electrode and cell comprising the same
HK1082958A1 (en) Tumor-lysing virus growing selectively in tumor cells
HK1083210A1 (en) Discharge member and container provided with the same
EP1435387A4 (en) The oncolytic microorganisms expressing hsp and uses thereof
AU2002306766A1 (en) Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
AU2002247689A1 (en) Influenza viruses with enhanced transcriptional and replicational capacities
AU2001257362A1 (en) The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
AU2002221515A1 (en) A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it
EP1316441A4 (en) Collection holder
EP1138526A3 (en) Spoked wheel with section in V-form
AU2001232254A1 (en) Solar radiation reflector and solar energy system comprising the solar radiationreflector
AU2002342464A1 (en) Xylanases with enhanced thermophilicity and alkalophilicity
WO2001077388A8 (en) Iterative analysis of non-responding population in the design of pharmacogenetic studies
AU2003257770A1 (en) Replicability virus which can express anti-tumour antibody with high efficiency and the use of it
EP1177207A4 (en) Dna encoding the prostate-specific membrane antigen-like gene and uses thereof
AU2002358217A1 (en) Improvements in or relating to energy storage devices
CA96355S (en) Dispensing container
AU2002313862A1 (en) A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it
AU2001288940A1 (en) Gene and sequence variation associated with cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application